Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD

ClinicalTrials.gov ID: NCT03386474

Public ClinicalTrials.gov record NCT03386474. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 9:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 24-week, Double-masked, Multicenter, Two-arm Extension Study to Collect Safety and Efficacy Data on Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2301 Study

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this extension study was to assess the safety and efficacy of the new formulation of brolucizumab 6 mg ophthalmic solution when given to the same patients who received brolucizumab in the core trial CRTH258A2301 (also known as CRTH258-C002). The medical condition treated in the core and extension trials was neo-vascular age-related macular degeneration (nAMD).

Study identification

NCT ID
NCT03386474
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novartis Pharmaceuticals
Industry
Enrollment
151 participants

Conditions and interventions

Eligibility (public fields only)

Age range
50 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 14, 2018
Primary completion
Sep 5, 2018
Completion
Sep 5, 2018
Last update posted
Jan 4, 2021

2018

United States locations

U.S. sites
63
U.S. states
24
U.S. cities
59
Facility City State ZIP Site status
Novartis Investigative Site Peoria Arizona 85381
Novartis Investigative Site Phoenix Arizona 85014
Novartis Investigative Site Arcadia California 91006
Novartis Investigative Site Huntington Beach California 92647
Novartis Investigative Site La Jolla California 92093
Novartis Investigative Site Loma Linda California 92354
Novartis Investigative Site Mountain View California 94040
Novartis Investigative Site Oakland California 94609
Novartis Investigative Site Redlands California 92374
Novartis Investigative Site Sacramento California 95841
Novartis Investigative Site Colorado Springs Colorado 80909
Novartis Investigative Site Golden Colorado 80401
Novartis Investigative Site Bridgeport Connecticut 06606
Novartis Investigative Site New London Connecticut 06320
Novartis Investigative Site Altamonte Springs Florida 32701
Novartis Investigative Site Deerfield Beach Florida 33064
Novartis Investigative Site Fort Myers Florida 33912-7125
Novartis Investigative Site Ocala Florida 34474
Novartis Investigative Site Palm Beach Gardens Florida 33410
Novartis Investigative Site Pensacola Florida 32503
Novartis Investigative Site Sarasota Florida 34239
Novartis Investigative Site Tallahassee Florida 32308
Novartis Investigative Site Vero Beach Florida 32960
Novartis Investigative Site Winter Haven Florida 33880
Novartis Investigative Site Boise Idaho 83713
Novartis Investigative Site Bloomington Illinois 61704
Novartis Investigative Site Indianapolis Indiana 46280
Novartis Investigative Site Leawood Kansas 66211
Novartis Investigative Site Shawnee Mission Kansas 66204
Novartis Investigative Site Portland Maine 04102
Novartis Investigative Site Baltimore Maryland 21237-4350
Novartis Investigative Site Waldorf Maryland 20602
Novartis Investigative Site Las Vegas Nevada 89144
Novartis Investigative Site Reno Nevada 89502
Novartis Investigative Site Toms River New Jersey 08755
Novartis Investigative Site Albuquerque New Mexico 87102
Novartis Investigative Site Rochester New York 14620
Novartis Investigative Site Rochester New York 14642
Novartis Investigative Site Shirley New York 11967
Novartis Investigative Site Syracuse New York 13224
Novartis Investigative Site Charlotte North Carolina 28210
Novartis Investigative Site Southern Pines North Carolina 28387
Novartis Investigative Site Cleveland Ohio 44122
Novartis Investigative Site Cleveland Ohio 44195
Novartis Investigative Site Dublin Ohio 43016
Novartis Investigative Site Fairfield Ohio 45014
Novartis Investigative Site Camp Hill Pennsylvania 17011
Novartis Investigative Site Nashville Tennessee 37203
Novartis Investigative Site Abilene Texas 79606
Novartis Investigative Site Austin Texas 78731
Novartis Investigative Site Fort Worth Texas 76104
Novartis Investigative Site Houston Texas 77025
Novartis Investigative Site Houston Texas 77030
Novartis Investigative Site Plano Texas 75093
Novartis Investigative Site San Antonio Texas 78215
Novartis Investigative Site San Antonio Texas 78240
Novartis Investigative Site Richmond Virginia 23235
Novartis Investigative Site Warrenton Virginia 20186
Novartis Investigative Site Silverdale Washington 98383
Novartis Investigative Site Spokane Washington 99204
Novartis Investigative Site University Place Washington 98467
Novartis Investigative Site Morgantown West Virginia 26506
Novartis Investigative Site Milwaukee Wisconsin 53226

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03386474, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 4, 2021 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03386474 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →